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Background: Certain immune-mediated diseases (IMDs) have been associated with increased risk for cardiovascular
disorders. The aim of the present study was to examine whether there is an association between 32 different IMDs
and first hospitalization for ischemic or hemorrhagic stroke.
Methods: All individuals in Sweden hospitalized with a main diagnosis of IMD (without previous or coexisting
stroke), between January 1, 1987 and December 31, 2008 (n = 216,291), were followed for first hospitalization for
ischemic or hemorrhagic stroke. The reference population was the total population of Sweden. Adjusted
standardized incidence ratios (SIRs) for ischemic and hemorrhagic stroke were calculated.
Results: Totally 20 and 15 of the 32 IMDs studied, respectively, were associated with an increased risk of ischemic
and hemorrhagic stroke during the follow-up. The overall risks of ischemic and hemorrhagic stroke during the first
year after hospitalization for IMD were 2.02 (95 % CI 1.90–2.14) and 2.65 (95 % CI 2.27–3.08), respectively. The overall
risk of ischemic or hemorrhagic stroke decreased over time, to 1.50 (95 % CI 1.46–1.55) and 1.83 (95 % CI 1.69–1.98),
respectively, after 1–5 years, and 1.29 (95 % CI 1.23–1.35) and 1.47 (95 % CI 1.31–1.65), respectively, after 10+ years.
The risk of hemorrhagic stroke was ≥2 during the first year after hospitalization for seven IMDs: ankylosing
spondylitis (SIR = 8.11), immune thrombocytopenic purpura (SIR = 8.60), polymyalgia rheumatica (SIR = 2.06), psoriasis
(SIR = 2.88), rheumatoid arthritis (SIR = 3.27), systemic lupus erythematosus (SIR = 8.65), and Wegener´s
granulomatosis (SIR = 5.83). The risk of ischemic stroke was ≥2 during the first year after hospitalization for twelve
IMDs: Addison’s disease (SIR = 2.71), Crohn´s disease (SIR = 2.15), Grave´s disease (SIR = 2.15), Hashimoto´s thyroiditis
(SIR = 2.99), immune thrombocytopenic purpura (SIR = 2.35), multiple sclerosis (SIR = 3.05), polymyositis/
dermatomyositis (SIR = 3.46), rheumatic fever (SIR = 3.91), rheumatoid arthritis (SIR = 2.08), Sjögren’s syndrome
(SIR = 2.57), systemic lupus erythematosus (SIR = 2.21), and ulcerative colitis (SIR = 2.15).
Conclusions: Hospitalization for many IMDs is associated with increased risk of ischemic or hemorrhagic stroke. The
findings suggest that several IMDs are linked to cerebrovascular disease.* Correspondence: bengt.zoller@med.lu.se
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Ischemic and hemorrhagic stroke are major causes of
morbidity and mortality worldwide [1]. During recent
years it has become clear that systemic inflammation may
enhance atherogenesis [2-4]. Immune-mediated diseases
(IMDs) are a heterogenous group of diseases that are char-
acterized by acute or chronic inflammation [2-8]. Some
IMDs have been associated with an increased risk for car-
diovascular disease [2-8]. IMDs may increase the cardio-
vascular disease risk through different mechanisms such
as autoreactive lymphocytes, autoantibodies, autoantigens,
epigenetic mechanisms, and inflammation driving the for-
mation, progression and rupture of atherosclerotic plaques
[2-8]. Inflammation may also affect the thrombotic risk by
suppressing fibrinolysis, upregulating procoagulants, and
downregulating anticoagulants [7]. Thus, certain IMDs
such as rheumatoid arthritis (RA) [3,5,6,8-12] and sys-
temic lupus erythematosus (SLE) [3,5,6,8,13-15] have been
associated with an increased risk of cardiovascular disease.
Enhanced atherogenesis has also been indicated in other
IMDs such as Sjögren´s disease [3,5,6,16], systemic vascu-
litis [3,5], inflammatory bowel disease [3,5,8,17], and psor-
iasis [8,18]. As a consequence of this, the risk of stroke has
been reported to be increased in patients with systemic
lupus erythematosus [19] and rheumatoid arthritis [20].
We hypothesized that not only IMDs such as SLE and
RA, but also a number of other less well-studied IMDs
have an increased risk of cardiovascular disease. More spe-
cifically, we aimed at determining whether IMDs increase
the risk for hospitalized ischemic or hemorrhagic stroke.
In a nationwide follow-up from 1987–2008 we have esti-
mated the risk of hospitalization with stroke in patients
hospitalized with 32 different IMDs without previous or
coexisting stroke.
Methods
This study was approved by the Ethics Committee of Lund
University, Sweden. Data used in this study contained in-
formation on all individuals registered as residents of Swe-
den [21]. It included individual-level information on age,
sex, occupation, geographic region of residence, hospital
diagnoses, and dates of hospital admissions in Sweden
(1964–2008), as well as date of emigration, and date and
cause of death [21]. The dataset was constructed using
several national Swedish data registers (reviewed by Rosen
and Hakulinen) [22], including, but not limited to, the
Swedish National Population and Housing Census (1960–
1990), the Total Population Register, the Multi-Generation
Register, and the Swedish Hospital Discharge Register
[23]. The data were released to us from the National
Board of Health and Welfare and Statistics Sweden.
Information retrieved from the various registers was
linked, at the individual level, via the national 10-digit
personal identification number assigned to each residentof Sweden for his or her lifetime. Registration numbers
were replaced by serial numbers to preserve anonymity.
As well as being used to track all records in the database
at the individual level, these serial numbers were used to
check that individuals with hospital diagnoses of ische-
mic or hemorrhagic stroke appeared only once during
the follow-up (for the first hospital diagnosis of ischemic
or hemorrhagic stroke during the study period).
The follow-up period for analysis of data in the present
study started on January 1, 1987 and continued until
hospitalization for ischemic or hemorrhagic stroke, death,
emigration, or the end of the study period (December 31,
2008). Data for first hospitalization for ischemic or
hemorrhagic stroke during the study period were retrieved
from the Hospital Discharge Register (1987–2008). This
study did not include data for hospital outpatients or
patients treated at primary health care centers.
Predictor variable
The predictor variable was hospitalization for an IMD,
diagnosed according to ICD-7, ICD-8, ICD-9, and ICD-
10 (Additional file 1 Table S1).
Outcome variable
Diagnosis of ischemic stroke was based on the 9th, and
10th revisions of the International Classification of Dis-
eases (ICD-9, and ICD-10). Cases of ischemic stroke
were identified using the following ICD codes: 433, 434,
435, 437.0, and 437.1 (ICD-9); and I63 (not I636), I65,
I66, I67.2, and I67.8 (ICD-10).
Diagnosis of hemorrhagic stroke was also based on
ICD-9, and ICD-10. Cases of hemorrhagic stroke were
identified using the following ICD codes: 431 and 432
(ICD-9); and I61 and I62 (ICD-10).
Individual-level variables adjusted for in the model
The individual-level variables were sex, age, time period,
geographic region of residence, socioeconomic status
(SES), and comorbidity.
Sex: male or female.
Age was divided into 5-year categories. Subjects of all
ages were included in the study.
Time period was divided into five time periods in order
to allow for adjustment for any change in hospitalization
rates over time: 1987–1991, 1992–1996, 1997–2001,
2002–2008.
Geographic region of residence was included as an in-
dividual-level variable to adjust for possible differences in
hospital admissions for ischemic or hemorrhagic stroke
between different geographic regions in Sweden. It was
categorized as: 1) large city (city with a population of
>200,000 (i.e., Stockholm, Gothenburg, or Malmo); 2)
Southern Sweden (both rural and urban); and 3) North-
ern Sweden (both rural and urban).
Table 1 Number of cases hospitalizations of IMD and
related conditions, 1987-2008
Men Women All
Immune-mediated disease No % No % No %
Addison disease 862 1.05 1190 0.89 2052 0.95
Amyotrophic lateral sclerosis 2376 2.89 2055 1.53 4431 2.05
Ankylosing spondylitis 2416 2.94 1061 0.79 3477 1.61
Autoimmune hemolytic
anemia
312 0.38 391 0.29 703 0.33
Behcet disease 146 0.18 138 0.10 284 0.13
Celiac disease 2639 3.21 4249 3.17 6888 3.18
Chorea minor 10 0.01 25 0.02 35 0.02
Crohn disease 9522 11.58 10700 7.98 20222 9.35
Diabetes mellitus type I 9068 11.02 7664 5.72 16732 7.74
Discoid lupus erythematosus 54 0.07 200 0.15 254 0.12
Grave disease 3764 4.58 18298 13.65 22062 10.20
Hashimoto thyroiditis 1440 1.75 5115 3.82 6555 3.03
Immune thrombocytopenic
purpura
1905 2.32 2039 1.52 3944 1.82
Localized scleroderma 90 0.11 422 0.31 512 0.24
Lupoid hepatitis 115 0.14 274 0.20 389 0.18
Multiple sclerosis 3492 4.25 6892 5.14 10384 4.80
Myasthenia gravis 935 1.14 1149 0.86 2084 0.96
Pernicious anemia 1663 2.02 1868 1.39 3531 1.63
Polyarteritis nodosa 437 0.53 386 0.29 823 0.38
Polymyalgia rheumatica 5313 6.46 11183 8.34 16496 7.63
Polymyositis/dermatomyositis 404 0.49 667 0.50 1071 0.50
Primary biliary cirrhosis 124 0.15 675 0.50 799 0.37
Psoriasis 4471 5.44 4558 3.40 9029 4.17
Reiter disease 280 0.34 58 0.04 338 0.16
Rheumatic fever 236 0.29 228 0.17 464 0.21
Rheumatoid arthritis 12080 14.69 32531 24.27 44611 20.63
Sarcoidosis 2847 3.46 2518 1.88 5365 2.48
Sjören syndrome 125 0.15 1175 0.88 1300 0.60
Systemic lupus erythematosus 742 0.90 3437 2.56 4179 1.93
Systemic sclerosis 402 0.49 1356 1.01 1758 0.81
Ulcerative colitis 12963 15.76 10647 7.94 23610 10.92
Wegener granulomatosis 1025 1.25 884 0.66 1909 0.88
All 82258 100.00 134033 100.00 216291 100.00
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each individual’s occupation into one of six categories: 1)
blue-collar worker, 2) white-collar worker, 3) professional,
4) self-employed, 5) farmer, and 6) non-employed (Indivi-
duals without paid employment). Homemakers and stu-
dents without an occupation were categorized on the
basis of their husband’s, father’s or mother’s occupation. If
that was not possible, they were included in the “non-
employed” category. For individuals aged <20 years, par-
ental occupation was used.
Comorbidity was defined as the first hospital diagnosis
at follow up (1987–2008) of the following: 1) chronic
lower respiratory diseases (490–496 (ICD-9), and J40–J49
(ICD-10)); 2) obesity (278A (ICD-9), and E65–E68 (ICD-
10)); 3) alcoholism and alcohol-related liver disease (291
and 303 (ICD-9), and F10 and K70 (ICD-10)); 4) type 2
diabetes mellitus (250 (age >29 years) (ICD-9), and E11-
E14 (ICD-10)); 5) hypertension (401–405 (ICD-9), and
I10–I15 (ICD-10)); 6) atrial fibrillation (427D (ICD-9), and
I48 (ICD-10)); 7) heart failure (428 (ICD-9), and I50 (ICD-
10)); 8) renal disease (580–591 and 753B (ICD-9), and
N00-N19, Q61 (ICD-10)); 9) sepsis (036,038 (ICD-9), and
A39-A41 (ICD-10)); and 10) coronary heart disease (410–
414 (ICD-9), and I20-I25 (ICD-10)).
Statistical analysis
Person-years at risk (i.e., number of persons at risk multi-
plied by time at risk) were calculated from the time at
which subjects were included in the study (in 1987 or later)
until first hospitalization for ischemic or hemorrhagic
stroke, death, emigration, or the end of the study period.
Person years for IMD patients were calculated from dis-
charge of first hospitalization for IMD (IMD patients with
previous stroke before the first IMD hospitalization or at
the same hospitalization as the first IMD hospitalization,
were excluded). The expected number of cases was based
on the number of cases in the reference group. SIRs were
calculated as the ratio of observed (O) and expected (E)
number of ischemic or hemorrhagic stroke cases using the










Where o ¼Poj denotes the total observed number of
cases in the study group; E (expected number of cases)
is calculated by applying stratum-specific standard inci-
dence rates λj
 
obtained from the reference group to
the stratum-specific person-years (n) of risk for the
study group; oj represents the observed number of cases
that the cohort subjects contribute to the jth stratum;
and J represents the strata defined by cross-classification
of the following adjustment variables: age, sex, timeperiod, SES, geographic region of residence, and comor-
bidity[24]. Ninety-five percent confidence intervals (95 %
CIs) were calculated assuming a Poisson distribution
[24]. All analyses were performed using SAS version 9.2
(SAS Institute, Cary, NC, USA).
Results
Table 1 shows the number of people admitted to hos-
pital with each of the selected IMDs during the study
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hospitalization for IMD or stroke at the same time as
first IMD hospitalization were excluded from Table 1.
Totally 8113 IMD patient with previous or coexisting is-
chemic stroke and 1416 with hemorrhagic stroke were
excluded. A total of 216,291 individuals were hospita-
lized with an IMD (82,258 males and 134,033 females)
(Table 1). The three most common immune-mediated
diseases were rheumatoid arthritis (44,611 cases), ulcera-
tive colitis (23,610), and Graves’ disease (22,062). Totally
66,509 patients with ischemic stroke and 428,031
patients with hemorrhagic strokes from 1987–2008 were
included (Table 2), of whom 10,905 (9,437 ischemic and
1,468 hemorrhagic strokes) were subsequently admitted
to hospital after a first hospitalization for IMD (Table 2).
The comorbidities (defined as main or second hospital
diagnosis) adjusted for are presented in Table 2.
Hemorrhagic stroke
A total of 66,509 individuals were hospitalized with a main
diagnosis of hemorrhagic stroke (Table 2), of whom 1,468
(22 % of hemorrhagic strokes) had been admitted to hos-
pital due to an IMD (Table 2). The risk of hemorrhagic
stroke was significantly increased during the whole follow-
up period for 15 of the 32 IMDs studied (Table 3). The
overall risk of hemorrhagic stroke during the first year
after hospitalization for an IMD was 265 (95 % CI 227–
308). The overall risk of hemorrhagic stroke decreased
over time, to 183 after 1–5 years (95 % CI 169–198),
163 after 5–10 years (95 % CI 147–180) and 147 after
10+ years (95 % CI 131–165).
The risk of hemorrhagic stroke was ≥2 during the first
year after hospitalization for seven IMD (Table 3): anky-
losing spondylitis, immune thrombocytopenic purpura,
polymyalgia rheumatica, psoriasis, rheumatoid arthritis,
systemic lupus erythematosus, and Wegener´s granulo-
matosis. For seven IMDs, the risk of hemorrhagic stroke
was increased 10+ years after hospitalization (Table 3):
ankylosing spondylitis, celiac disease, Crohn´s disease,
Graves’ disease, localized scleroderma, polymyalgia rheu-
matica, and rheumatoid arthritis.
Hemorrhagic stroke and age and sex
The overall risk of hemorrhagic stroke was increased for
both sexes at all different follow-up periods (Additional
file 1 Tables S2 and S3). The overall risk of hemorrhagic
stroke was increased in all age groups for both males
and females (<50, 50–59, 60–69, 70–79, and 80+ years)
(Additional file 1 Tables S4, S5 and S6).
Ischemic stroke
A total of 428,031 individuals were hospitalized with a main
diagnosis of ischemic stroke (Table 2), of whom 9,437
(22 % of all ischemic stroke cases) had been admitted tohospital due to an IMD (Table 2). The variables for which
the SIRs were adjusted are presented in Table 1. The risk of
ischemic stroke was increased during the whole follow-up
period for 20 of the 32 IMDs studied (Table 4). The overall
risk of ischemic stroke during the first year after
hospitalization for an IMD was 202 (95 % CI 190–214).
The overall risk of ischemic stroke decreased over time,
to150 after 1–5 years (95 % CI 146–155), 138 after 5–
10 years (95 % CI 133–143) and 129 after 10+ years
(95 % CI 123–135) (Table 4).
The risk of ischemic stroke was ≥2 during the first year
after hospitalization for twelve IMDs (Table 4): Addison’s
disease, Crohn´s disease, Grave´s disease, Hashimoto´s
thyroiditis, immune thrombocytopenic purpura, multiple
sclerosis, polymyositis/dermatomyositis, rheumatic fever,
rheumatoid arthritis, Sjögren’s syndrome, systemic lupus
erythematosus, and ulcerative colitis. For seven IMDs, the
risk of ischemic stroke was increased 10+ years after
hospitalization: diabetes mellitus type 1, Graves’ disease,
Hashimoto’s thyroiditis, pernicious anemia, polymyalgia
rheumatica, psoriasis, and rheumatoid arthritis (Table 4).
Ischemic stroke and age and sex
The overall risk of ischemic or hemorrhagic stroke was
increased for both sexes at all different follow-up periods
(Additional file 1 Tables S7 and S8). The overall risk of
ischemic stroke was increased in all age groups for both
sexes (<50, 50–59, 60–69, 70–79, and 80+ years) (Add-
itional file 1 Tables S9, S10 and S11).
Time period and hemorrhagic and ischemic stroke
The overall risk for both hemorrhagic and ischemic stroke
was slightly higher between 1987 and 1996 (1.98 95 % CI
1.78-2.20 and 1.51 95 % CI 1.45-1.57, respectively) than
between 1997 and 2008 (1.58 95 % CI 1.48-1.69 and 1.38
95 % CI 1.34-1.41, respectively) (Additional file 1 Tables
S12 and S13).
Discussion
The present study is the first nationwide study of IMDs and
ischemic and hemorrhagic stroke. The results indicate that
several IMDs increase the risk of hospitalization for both is-
chemic and/or hemorrhagic stroke. The relative risk of is-
chemic and hemorrhagic stroke during the first year after
hospitalization with certain IMDs was even higher than the
risks associated with many traditional risk factors for ische-
mic and hemorrhagic stroke [1,25]. Although it declined
over time, the overall risk of ischemic and hemorrhagic
stroke remained elevated for 10 or more years for some
IMDs. The results of our study are in line with previous
studies linking rheumatoid arthritis [3,5,6,8-12,20], systemic
lupus erythematosus [3,5,6,8,13-15,19], Sjögren´s disease
[3,5,6,16], systemic vasculitis [3,5], inflammatory bowel dis-
ease [3,5,8,17], and psoriasis [8,18] to an increased risk of
Table 2 Number of cases of stroke, 1987-2008












Characteristics No. % No. % No. % No. %
Gender
Men 36639 55.1 21680250.7 566 38.6 3216 34.1
Women 29870 44.9 21122949.3 902 61.4 6221 65.9
Age at diagnosis
(yrs)
<50 5070 7.6 13632 3.2 73 5.0 221 2.3
50-59 6857 10.3 29285 6.8 120 8.2 439 4.7
60-69 12399 18.6 71089 16.6 249 17.0 1263 13.4
70-79 21079 31.7 14528833.9 476 32.4 3208 34.0
>= 80 21104 31.7 16873739.4 550 37.5 4306 45.6
Period of diagnosis
(yrs)
1987-91 13074 19.7 90088 21.0 134 9.1 832 8.8
1992-96 15114 22.7 11052525.8 299 20.4 2183 23.1
1997-01 15773 23.7 97993 22.9 389 26.5 2626 27.8
2002-08 22548 33.9 12942530.2 646 44.0 3796 40.2
Socioeconomic
status
Farmers 4797 7.2 34375 8.0 109 7.4 773 8.2
Self-employed 4911 7.4 31497 7.4 95 6.5 654 6.9
Professionals 4726 7.1 25561 6.0 70 4.8 438 4.6
White collar workers18912 28.4 11932027.9 476 32.4 2773 29.4
Workers 29487 44.3 19783346.2 653 44.5 4406 46.7
Others 3676 5.5 19445 4.5 65 4.4 393 4.2
Region of residence
Big cities 22409 33.7 14511933.9 429 29.2 2915 30.9
Northern Sweden 12936 19.4 80680 18.8 310 21.1 1972 20.9
Southern Sweden 31164 46.9 20223247.2 729 49.7 4550 48.2
Hospitalization for
obesity
Yes 114 0.2 703 0.2 2 0.1 30 0.3
No 66395 99.8 42732899.8 1466 99.9 9407 99.7
Hospitalization for
alcoholism
Yes 2265 3.4 7448 1.7 45 3.1 143 1.5




Yes 2067 3.1 18287 4.3 63 4.3 613 6.5
No 64442 96.9 40974495.7 1405 95.7 8824 93.5
Table 2 Number of cases of stroke, 1987-2008 (Continued)
Hospitalization for
hypertension
Yes 2254 3.4 16998 4.0 48 3.3 434 4.6
No 64255 96.6 41103396.0 1420 96.7 9003 95.4
Hospitalization for
diabetes type II
Yes 2425 3.6 28091 6.6 77 5.2 726 7.7




Yes 4174 6.3 47257 11.0 134 9.1 1351 14.3




Yes 4619 6.9 63904 14.9 129 8.8 1749 18.5




Yes 2656 4.0 19793 4.6 105 7.2 718 7.6
No 63853 96.0 40823895.4 1363 92.8 8719 92.4
Hospitalization for
sepsis
Yes 2167 3.3 15738 3.7 77 5.2 615 6.5




Yes 9323 14.0 10889525.4 234 15.9 2589 27.4
No 57186 86.0 31913674.6 1234 84.1 6848 72.6
All 66509 100.0 428031100.01468 100.0 9437 100.0
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study from these other studies is its comparison of large
numbers of patients and 32 types of IMDs with the general
population in a nationwide setting, as well as the long-term
follow-up of patients and the determination of risk for both
ischemic and hemorrhagic stroke. Moreover, we also found
a number of novel associations between IMDs and ischemic
and hemorrhagic stroke. The results of the present study
suggest that increased risk of subsequent ischemic and
hemorrhagic stroke is a common feature of several IMDs,
not just selected conditions such as systemic lupus erythe-
matosus [19] and rheumatoid arthritis [20].
Although the increased risk of ischemic and hemorrhagic
stroke may have different underlying causes in different
IMDs, a general link between systemic inflammation and
atherothrombosis has been indicated [2-8]. In some condi-
tions, such as in immune thrombocytopenic purpura,
Table 3 SIR for subsequent hemorrhagic stroke of patients with IMD
Follow-up interval (years)
<1 1-5 5-10 >= 10 All
Immune-mediated
diseases
O SIR 95 % CI O SIR 95 % CI O SIR 95 % CI O SIR 95 % CI O SIR 95 % CI
Addison´s disease 2 2.70 0.25 9.94 2 0.64 0.06 2.34 1 0.42 0.00 2.41 1 0.55 0.00 3.17 6 0.74 0.27 1.63
Amyotrophic lateral
sclerosis
1 0.47 0.00 2.68 2 1.30 0.12 4.78 1 1.82 0.00 10.42 0 4 0.89 0.23 2.30
Ankylosing spondylitis 6 8.11 2.92 17.76 15 3.43 1.92 5.68 7 1.66 0.66 3.44 14 2.28 1.24 3.84 42 2.72 1.96 3.67
Autoimmune hemolytic
anemia
1 3.13 0.00 17.91 4 2.96 0.77 7.66 1 1.15 0.00 6.59 2 2.99 0.28 10.98 8 2.49 1.06 4.93
Behcet´s disease 1 33.33 0.01 191.08 0 0 0 1 1.67 0.00 9.55
Celiac disease 2 3.57 0.34 13.13 6 2.08 0.75 4.56 7 2.69 1.07 5.58 8 2.65 1.13 5.25 23 2.54 1.61 3.81
Chorea minor 0 0 0 0 0
Crohn disease 5 1.47 0.46 3.46 47 2.60 1.91 3.46 19 1.19 0.72 1.87 24 1.57 1.00 2.34 95 1.80 1.46 2.21
Diabetes mellitus type I 0 2 2.50 0.24 9.19 1 1.11 0.00 6.37 2 1.01 0.09 3.70 5 1.32 0.42 3.10
Discoid lupus
erythematosus
1 11.11 0.00 63.69 1 2.33 0.00 13.33 0 0 2 1.87 0.18 6.87
Grave´s disease 8 1.53 0.65 3.02 58 1.77 1.35 2.29 48 1.61 1.18 2.13 41 1.48 1.06 2.02 155 1.62 1.38 1.90




8 8.60 3.67 17.03 12 2.81 1.45 4.92 6 2.18 0.79 4.78 2 1.23 0.12 4.54 28 2.93 1.94 4.23
Localized scleroderma 0 1 0.93 0.00 5.36 1 0.85 0.00 4.90 6 4.32 1.55 9.46 8 2.11 0.90 4.17
Lupoid hepatitis 0 0 0 0 0
Multiple sclerosis 4 1.82 0.47 4.70 15 1.36 0.76 2.25 9 1.09 0.49 2.08 6 0.94 0.34 2.06 34 1.22 0.84 1.71
Myasthenia gravis 1 1.22 0.00 6.99 8 2.09 0.89 4.14 6 2.17 0.78 4.76 0 15 1.62 0.90 2.68
Pernicious anemia 4 2.15 0.56 5.56 18 1.67 0.99 2.65 13 1.52 0.81 2.61 7 0.99 0.39 2.06 42 1.49 1.07 2.01
Polyarteritis nodosa 2 5.41 0.51 19.88 0 0.00 0.54 2.19 3 1.91 0.36 5.66 0 5 1.00 0.31 2.34
Polymyalgia rheumatica 21 2.06 1.28 3.16 78 1.42 1.12 1.77 65 1.67 1.29 2.13 40 1.49 1.06 2.03 204 1.56 1.35 1.79
Polymyositis/
dermatomyositis
1 2.63 0.00 15.08 3 1.95 0.37 5.77 1 1.18 0.00 6.74 1 2.08 0.00 11.94 6 1.85 0.66 4.04
Primary biliary cirrhosis 1 2.08 0.00 11.94 3 1.76 0.33 5.22 2 2.17 0.20 7.99 0 6 1.87 0.67 4.10
Psoriasis 9 2.88 1.31 5.50 32 1.83 1.25 2.59 23 1.51 0.95 2.26 21 1.32 0.81 2.02 85 1.64 1.31 2.03
Reiter´s disease 0 1 2.94 0.00 16.86 1 2.56 0.00 14.70 0 2 1.42 0.13 5.22
Rheumatic fever 1 7.69 0.00 44.09 0 0 1 1.72 0.00 9.88 2 1.04 0.10 3.81
Rheumatoid arthritis 65 3.27 2.52 4.17 191 2.03 1.76 2.34 109 1.92 1.57 2.31 61 1.78 1.36 2.29 426 2.08 1.89 2.29
Sarcoidosis 3 2.48 0.47 7.34 12 1.87 0.96 3.28 14 2.26 1.23 3.80 6 0.79 0.28 1.73 35 1.64 1.14 2.28
Sjögren´s syndrome 0 3 1.35 0.25 4.00 2 1.03 0.10 3.77 0 5 0.81 0.26 1.90
Systemic lupus
erythematosus
9 8.65 3.92 16.50 13 2.89 1.53 4.95 4 1.17 0.31 3.03 6 1.91 0.69 4.19 32 2.65 1.81 3.74
Systemic sclerosis 2 3.17 0.30 11.67 5 2.67 0.84 6.29 3 2.73 0.51 8.07 2 3.45 0.33 12.68 12 2.87 1.48 5.03
Ulcerative colitis 7 1.45 0.57 3.00 40 1.45 1.03 1.97 28 1.21 0.80 1.74 33 1.44 0.99 2.02 108 1.37 1.13 1.66
Wegener´s
granulomatosis
6 5.83 2.10 12.76 3 0.90 0.17 2.67 2 1.08 0.10 3.95 0 11 1.47 0.73 2.63
All 175 2.65 2.27 3.08 602 1.83 1.69 1.98 396 1.63 1.47 1.80 295 1.47 1.31 1.65 1468 1.75 1.66 1.84
O=observed number of cases; SIR = standardized incidence ratio; CI = confidence interval.
Bold type: 95 % CI does not include 1.00.
Adjusted for age, period, socioeconomic status, region of residence, hospitalization of chronic lower respiratory diseases, obesity, alcoholism, hypertension,
diabetes, atrial fibrillation, heart failure, renal disease, sepsis, and coronary heart disease.
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Table 4 SIR for subsequent ischemic stroke of patients with IMD
Follow-up interval (years)
<1 1-5 5-10 >= 10 All
Immune-mediated
diseases
O SIR 95 % CI O SIR 95 % CI O SIR 95 % CI O SIR 95 % CI O SIR 95 % CI
Addison´s disease 14 2.71 1.48 4.56 28 1.17 0.78 1.69 30 1.90 1.28 2.72 11 0.97 0.48 1.74 83 1.48 1.18 1.83
Amyotrophic lateral
sclerosis
7 0.53 0.21 1.10 16 1.52 0.87 2.47 7 1.77 0.70 3.67 2 1.15 0.11 4.23 32 1.09 0.74 1.54
Ankylosing spondylitis 8 1.62 0.69 3.21 44 1.55 1.13 2.08 24 0.98 0.63 1.46 35 1.08 0.75 1.50 111 1.23 1.01 1.48
Autoimmune hemolytic
anemia
4 1.45 0.38 3.75 12 1.00 0.51 1.75 19 2.51 1.51 3.93 5 1.23 0.39 2.90 40 1.51 1.08 2.06
Behcet´s disease 1 4.00 0.00 22.93 1 0.65 0.00 3.70 0 1 1.43 0.00 8.19 3 0.78 0.15 2.29
Celiac disease 9 2.17 0.99 4.14 29 1.28 0.86 1.84 21 1.17 0.72 1.78 26 1.47 0.96 2.15 85 1.36 1.09 1.68
Chorea minor 0 1 2.27 0.00 13.03 0 0 1 1.11 0.00 6.37
Crohn disease 49 2.15 1.59 2.84 160 1.33 1.13 1.55 103 1.11 0.91 1.35 97 1.15 0.93 1.40 409 1.28 1.16 1.41
Diabetes mellitus type I 1 6.25 0.00 35.83 2 0.45 0.04 1.65 5 2.75 0.87 6.46 17 5.00 2.91 8.02 25 2.54 1.64 3.76
Discoid lupus
erythematosus
3 4.23 0.80 12.51 3 0.99 0.19 2.92 1 0.47 0.00 2.70 3 1.55 0.29 4.60 10 1.28 0.61 2.37
Grave´s disease 101 2.15 1.76 2.62 402 1.39 1.26 1.53 348 1.36 1.22 1.51 276 1.27 1.12 1.43 1127 1.39 1.31 1.48




16 2.35 1.34 3.83 55 1.77 1.33 2.30 19 0.94 0.57 1.48 14 1.20 0.65 2.01 104 1.49 1.22 1.81
Localized scleroderma 2 1.28 0.12 4.71 13 1.25 0.66 2.14 18 1.72 1.01 2.72 11 1.04 0.51 1.86 44 1.33 0.97 1.79
Lupoid hepatitis 3 4.48 0.84 13.25 4 1.98 0.52 5.12 0 0 7 2.10 0.83 4.36
Multiple sclerosis 40 3.05 2.18 4.15 73 1.09 0.85 1.37 55 1.11 0.83 1.44 35 0.95 0.66 1.32 203 1.22 1.06 1.40
Myasthenia gravis 6 1.01 0.36 2.21 38 1.36 0.96 1.87 23 1.20 0.76 1.80 13 1.08 0.57 1.85 80 1.23 0.97 1.53
Pernicious anemia 25 1.56 1.01 2.31 138 1.49 1.25 1.76 89 1.23 0.99 1.52 74 1.44 1.13 1.80 326 1.40 1.25 1.56
Polyarteritis nodosa 5 1.23 0.39 2.89 20 1.30 0.79 2.02 11 1.05 0.52 1.88 10 1.13 0.54 2.08 46 1.19 0.87 1.58
Polymyalgia rheumatica 165 1.76 1.50 2.05 761 1.50 1.39 1.61 529 1.54 1.41 1.68 322 1.53 1.37 1.71 1777 1.54 1.47 1.61
Polymyositis/
dermatomyositis
10 3.46 1.65 6.39 13 1.19 0.63 2.03 6 1.07 0.38 2.34 5 1.73 0.55 4.07 34 1.52 1.05 2.13
Primary biliary cirrhosis 4 1.54 0.40 3.98 11 1.45 0.72 2.60 4 0.91 0.24 2.35 1 2.17 0.00 12.46 20 1.33 0.81 2.05
Psoriasis 44 1.92 1.39 2.58 217 1.65 1.44 1.89 163 1.53 1.30 1.78 144 1.41 1.19 1.66 568 1.56 1.44 1.70
Reiter´s disease 0 5 2.02 0.64 4.76 6 2.47 0.89 5.41 2 0.56 0.05 2.07 13 1.47 0.78 2.52
Rheumatic fever 5 3.91 1.23 9.19 10 1.66 0.79 3.06 14 3.04 1.65 5.11 7 1.81 0.72 3.75 36 2.28 1.59 3.16
Rheumatoid arthritis 345 2.08 1.86 2.31 1266 1.66 1.57 1.75 663 1.45 1.34 1.56 326 1.30 1.16 1.45 2600 1.59 1.53 1.65
Sarcoidosis 9 0.97 0.44 1.85 70 1.43 1.12 1.81 51 1.12 0.83 1.47 56 1.08 0.81 1.40 186 1.19 1.03 1.38
Sjögren´s syndrome 10 2.57 1.22 4.75 28 1.38 0.92 1.99 15 0.96 0.54 1.59 15 1.26 0.70 2.08 68 1.31 1.02 1.67
Systemic lupus
erythematosus
19 2.21 1.33 3.46 88 2.33 1.87 2.87 54 1.92 1.44 2.51 30 1.26 0.85 1.80 191 1.94 1.68 2.24
Systemic sclerosis 11 1.90 0.94 3.41 28 1.22 0.81 1.77 11 1.19 0.59 2.14 2 0.39 0.04 1.43 52 1.21 0.90 1.58
Ulcerative colitis 71 2.15 1.68 2.71 231 1.27 1.11 1.45 162 1.09 0.92 1.27 146 1.05 0.89 1.24 610 1.21 1.12 1.31
Wegener´s
granulomatosis
11 1.66 0.82 2.98 12 0.47 0.24 0.83 26 1.54 1.00 2.25 12 1.69 0.87 2.96 61 1.09 0.83 1.40
All 1075 2.02 1.90 2.14 3990 1.50 1.46 1.55 2592 1.38 1.33 1.43 1780 1.29 1.23 1.35 9437 1.46 1.43 1.49
O=observed number of cases; SIR = standardized incidence ratio; CI = confidence interval.
Bold type: 95 % CI does not include 1.00.
Adjusted for age, period, socioeconomic status, region of residence, hospitalization of chronic lower respiratory diseases, obesity, alcoholism, hypertension,
diabetes, atrial fibrillation, heart failure, renal disease, sepsis, and coronary heart disease.
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http://www.biomedcentral.com/1471-2377/12/41hemorrhagic stroke may occur as the direct result of
thrombocytopenia. The formation of autoantibodies may,
in special cases, also contribute to stroke [26]. The
increased risk of stroke may be specific for more severe
cases of IMDs, since the patients in our study had been ad-
mitted to hospital. The effects of treatment—corticosteroids
promote hemostasis [27]—and the effect of inflammation
on coagulation [7] may also contribute to the identified
associations. Hypothetically, the fact that the risk of ische-
mic and hemorrhagic stroke decreased over time may sug-
gest that it is linked to the inflammatory activity of the
IMDs, which is likely to decrease over time due to treat-
ment. In line with this hypothesis, in several studies disease
activity appears to be linked with atherosclerosis progres-
sion [2-8,28,29]. However, as we lack treatment data, we
cannot prove this hypothesis but in this context it is inter-
esting that the relative risk of both hemorrhagic and ische-
mic stroke was lower between 1997 and 2008 than between
1987 and 1996 (Additional file 1 Tables S12 and S13).
The present study has certain limitations. For example,
we had no data on general cardiovascular disease risk fac-
tors such as weight, smoking, and diet. It is unrealistic to
gather such data for an entire national population. How-
ever, we did adjust for socioeconomic status, which is asso-
ciated with risk factors such as smoking. Aspirin and non-
steroidal anti-inflammatory drugs (NSAID) may affect the
risk of ischemic and hemorrhagic stroke [30,31]. However,
we had no access to treatment data. Adjustment was, how-
ever, made for several comorbidities (chronic lower respira-
tory diseases, obesity, alcoholism and alcohol-related liver
disease, type 2 diabetes mellitus, hypertension, atrial fibrilla-
tion, coronary heart diseases, heart failure, renal disease and
sepsis). Still, residual bias may remain due to hospitalization
of the most severe cases with IMD. However, all cases with
previous or coexisting stroke were excluded to avoid selec-
tion bias. Totally, 8113 IMD patients with previous or coex-
isting ischemic stroke and 1416 with hemorrhagic stroke
were excluded from the study, which in turn instead may
underestimate the stroke risk. In fact, our results are within
the limit for published cardiovascular disease risk in IMDs
like RA [3,5,6,8-12,20] and SLE [3,5,6,8,13-15,19]. Thus, the
estimated risks of stroke in IMD patients appear to be fairly
valid. Anyway, the present study reflects the real world risks
for stroke among hospitalized IMD (without previous
stroke or at the same time as first hospitalization for IMD).
All cases of ischemic and hemorrhagic stroke in Sweden
should, according to official guidelines, be treated at hospi-
tals [32]. Moreover, hospitalization incidence rates were cal-
culated for the whole follow-up period, divided into five
time periods, and adjustments were made for possible
changes in hospitalization rates over time.
This study also has a number of strengths. The study
reflects the situation in real world medicine during
22 years in a country with a high standard in the medicaldiagnosis [22,23,33-35]. The study population included
all individuals clinically diagnosed with IMD and ische-
mic and hemorrhagic stroke in hospital during the study
period, which eliminated recall bias. Because of the per-
sonal identification number assigned to each resident in
Sweden, it was possible to trace all subjects for the
whole follow-up period. Data on occupation were 992 %
complete (1980 and 1990 censuses), which enabled us to
adjust our models for socioeconomic status. A further
strength of the present study was the use of validated
hospital discharge data. The Hospital Discharge Register
has high validity [22,23,33-35], especially for cardiovas-
cular disorders such as stroke, for which approximately
95 % of diagnoses have been shown to be correct [33-
35]. Though, the positive predictive value (PPV) may dif-
fer between diagnoses in the Swedish Hospital Discharge
Register, the PPV is generally around 85-95 % [35].
Conclusions
In summary, the risk of hospitalization for ischemic and
hemorrhagic stroke was, for several immune-mediated dis-
eases studied, found to be significantly associated. The risk
of ischemic and hemorrhagic stroke during the first year
after hospitalization with an immune-mediated disease was
high for certain IMDs. Although it decreased over time, for
some IMDs the risk of ischemic and hemorrhagic stroke
remained elevated for more than 10 years. The findings of
the present study suggest that many IMDs are linked to
cerebrovascular disease. Future studies could elucidate the
mechanisms behind stroke in specific IMDs.
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